Multifocal ERG and Microperimetry Changes in Response to Ranibizumab Treatment of Neovascular AMD: Randomized Phase 2 Open-Label Study
Masumi G Asahi, Josh Wallsh, Spencer M Onishi, Shari Kuroyama, Ron P Gallemore Clinical Research Department, Retina Macula Institute, Torrance, CA, USACorrespondence: Ron P Gallemore Tel +1 (310) 944-9393Fax +1 (310) 944-3393Email rongallemoremd@gmail.comPurpose: To compare monthly versus pro re nat...
Guardado en:
Autores principales: | Asahi MG, Wallsh J, Onishi SM, Kuroyama S, Gallemore RP |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/850d71aba6d3485ba0deec01244a38a7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Testing the clinical value of multifocal electroretinography and microperimetry and the effects of intravitreal therapy with ranibizumab on macular function in the course of wet age-related macular degeneration: a 1-year prospective study
por: Reinsberg M, et al.
Publicado: (2017) -
Combination verteporfin photodynamic therapy ranibizumab-dexamethasone in choroidal neovascularization due to age-related macular degeneration: results of a phase II randomized trial
por: Gallemore RP, et al.
Publicado: (2017) -
Real-World Visual And Clinical Outcomes For Patients With Neovascular Age-Related Macular Degeneration Treated With Intravitreal Ranibizumab: An 8-Year Observational Cohort (AMD8)
por: Horner F, et al.
Publicado: (2019) -
Therapeutic Potential of the Ranibizumab Port Delivery System in the Treatment of AMD: Evidence to Date
por: Chen ER, et al.
Publicado: (2020) -
Gene expression levels of the insulin-like growth factor family in patients with AMD before and after ranibizumab intravitreal injections
por: Strzalka-Mrozik B, et al.
Publicado: (2017)